Moreover, the 36-month beta value for RNAZ is 1.40. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for RNAZ is 0.63M and currently, short sellers hold a 85.86% of that float. On March 24, 2025, RNAZ’s average trading volume was 2.61M shares.
RNAZ) stock’s latest price update
The stock of TransCode Therapeutics Inc (NASDAQ: RNAZ) has increased by 45.45 when compared to last closing price of 0.77. Despite this, the company has experienced a 44.00% gain in its stock price over the last five trading sessions. prnewswire.com reported 2025-03-13 that Clinical trial Safety Review Committee (SRC) approved opening of Cohort 4 based on favorable safety data from the three patients comprising Cohort 3 No significant safety or dose limiting toxicities reported in Cohorts 1, 2, or 3 Patients currently being evaluated for Cohort 4 eligibility PK and PD data from patients in Cohort 1 and Cohort 2 consistent with preclinical results and results from Phase 0 clinical trial BOSTON, March 13, 2025 /PRNewswire/ — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the Safety Review Committee (SRC) monitoring its Phase I clinical trial has unanimously approved opening of the fourth cohort of patients based on the SRC’s favorable review of Cohort 3 safety data. The therapeutic candidate being evaluated, TTX-MC138, is a first-in-class therapeutic designed to treat multiple metastatic cancers using antisense technology.
RNAZ’s Market Performance
TransCode Therapeutics Inc (RNAZ) has experienced a 44.00% rise in stock performance for the past week, with a -88.05% drop in the past month, and a -82.26% drop in the past quarter. The volatility ratio for the week is 31.72%, and the volatility levels for the past 30 days are at 28.54% for RNAZ. The simple moving average for the last 20 days is -39.58% for RNAZ stock, with a simple moving average of -91.74% for the last 200 days.
RNAZ Trading at -78.19% from the 50-Day Moving Average
After a stumble in the market that brought RNAZ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -98.31% of loss for the given period.
Volatility was left at 28.54%, however, over the last 30 days, the volatility rate increased by 31.72%, as shares sank -86.13% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -68.98% lower at present.
During the last 5 trading sessions, RNAZ rose by +44.00%, which changed the moving average for the period of 200-days by -97.90% in comparison to the 20-day moving average, which settled at $1.8537. In addition, TransCode Therapeutics Inc saw -66.77% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for RNAZ
Current profitability levels for the company are sitting at:
- -19.47 for the present operating margin
- 0.44 for the gross margin
The net margin for TransCode Therapeutics Inc stands at -19.82. The total capital return value is set at -8.88. Equity return is now at value -490.03, with -210.77 for asset returns.
Based on TransCode Therapeutics Inc (RNAZ), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -103.97. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is -181.32.
Currently, EBITDA for the company is -17.97 million with net debt to EBITDA at 0.12. When we switch over and look at the enterprise to sales, we see a ratio of -1.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.58.
Conclusion
To wrap up, the performance of TransCode Therapeutics Inc (RNAZ) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
